Covestor’s PharmaCyte Biotech PMCB Stock Holding History

Covestor’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$0	Hold	275	–	–	﹤0.01%	2722
2026 Q2	$0	Hold	275	–	–	﹤0.01%	2764
2026 Q1	$0	Hold	275	–	–	﹤0.01%	2665
2025 Q4	$0	Hold	275	–	–	﹤0.01%	2636
2025 Q3	$0	Hold	275	–	–	﹤0.01%	2652
2025 Q2	$0	Hold	275	–	–	﹤0.01%	2631
2025 Q1	$0	Hold	275	–	–	﹤0.01%	2611
2024 Q4	$0	Buy	275 +49	+22%	+$85	﹤0.01%	2620
2024 Q3	$0	Hold	226	–	–	﹤0.01%	2630
2024 Q2	$0	Hold	226	–	–	﹤0.01%	2632
2024 Q1	$1K	Hold	226	–	–	﹤0.01%	2076
2023 Q4	$0	Buy	226 +37	+20%	+$80	﹤0.01%	2580
2023 Q3	$0	Hold	189	–	–	﹤0.01%	2570
2023 Q2	$1K	Buy	+189	New	+$567	﹤0.01%	2003

Other funds holding PMCB

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return

Equitec Proprietary Markets Chicago, Illinois $400M AUM 66.98% 1-Year Est. Return

GSC

Ground Swell Capital Folly Beach, South Carolina $43.4M AUM 20.78% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

BFSG LLC Irvine, California $1.14B AUM 21.04% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Financial Consulate Hunt Valley, Maryland $899M AUM 14.82% 1-Year Est. Return

Covestor's PMCB Position: Q3 2026 in Review

Covestor held its PharmaCyte Biotech (PMCB) position steady in Q3 2026 at 275 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2722.

Covestor first reported a position in PMCB in Q2 2023 and has held it in 14 quarters since. The position peaked at $1K in Q1 2024. 9 funds tracked by Wall St. Rank hold PMCB as of Q3 2026.

Covestor held 275 shares of PharmaCyte Biotech worth $0 as of Q3 2026.
Covestor left its PharmaCyte Biotech share count unchanged in Q3 2026.
PharmaCyte Biotech made up ﹤0.01% of Covestor's portfolio in Q3 2026, its #2722 holding.
Covestor first reported a position in PharmaCyte Biotech in Q2 2023 and has held it in 14 quarters since.
Covestor's PharmaCyte Biotech position peaked at $1K in Q1 2024.
9 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q3 2026.

Based on Covestor's 13F filing for Q3 2026, filed 30 Oct 2026.